CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

被引：0

作者：

Chiorean, E. Gabriela

Von Hoff, Daniel D.

Ervin, Thomas J.

Arena, Francis P.

Infante, Jeffrey R.

Bathini, Venu Gopal

Wood, Tina Evans

Mainwaring, Paul N.

Muldoon, Robert T.

Clingan, Philip R.

Kunzmann, Volker

Ramanathan, Ramesh K.

Tabernero, Josep

Goldstein, David

Ko, Amy

Lu, Brian

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA

[3] Florida Canc Specialists, Englewood, FL USA

[4] Arena Oncol Associates, Lake Success, NY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Tennessee Oncol, Nashville, TN USA

[7] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA

[8] UAB Comprehens Canc Ctr, Birmingham, AL USA

[9] Mater Private Ctr Haematol & Oncol, South Brisbane, Australia

[10] Genesis Canc Ctr, Hot Springs, AR USA

[11] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[12] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[13] Vall dHebron Univ Hosp, Barcelona, Spain

[14] Prince Wales Hosp, Sydney, NSW, Australia

[15] Celgene Corp, Summit, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4058

引用

页数：1

共 50 条

[1] CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Chiorean, E. G.
Von Hoff, D. D.
Reni, M.
Arena, F. P.
Infante, J. R.
Bathini, V. G.
Wood, T. E.
Mainwaring, P. N.
Muldoon, R. T.
Clingan, P. R.
Kunzmann, V.
Ramanathan, R. K.
Tabernero, J.
Goldstein, D.
McGovern, D.
Lu, B.
Ko, A.
ANNALS OF ONCOLOGY, 2016, 27 (04) : 654 - 660
[2] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Moore, Malcolm J.
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Chiorean, E. Gabriela
Infante, Jeffrey R.
Hon, Jeremy K.
Biakhov, Mikhail Yu
Hingorani, Sunil R.
Ganju, Vinod
Weekes, Colin D.
Scheithauer, Werner
Ramanathan, Ramesh K.
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Romano, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
Ikeda, Masafumi
Ueno, Hideki
Ueno, Makoto
Mizuno, Nobumasa
Ioka, Tatsuya
Omuro, Yasushi
Nakajima, Takako
Furuse, Junji
ANNALS OF ONCOLOGY, 2014, 25
[4] Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
Scheithauer, W.
Von Hoff, D. D.
Ramanathan, R. K.
Moore, M.
Tabernero, J.
Goldstein, D.
Hammel, P.
Kunzmann, V.
Ko, A.
Romano, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S614 - S614
[5] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Tabernero, Josep
Chiorean, E. Gabriela
Infante, Jeffrey R.
Hingorani, Sunil R.
Ganju, Vinod
Weekes, Colin
Scheithauer, Werner
Ramanathan, Ramesh K.
Goldstein, David
Penenberg, Darryl N.
Romano, Alfredo
Ferrara, Stefano
Von Hoff, Daniel D.
ONCOLOGIST, 2015, 20 (02): : 143 - 150
[6] Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Chiorean, E. Gabriela
Infante, Jeffrey R.
Moore, Malcolm J.
Seay, Thomas E.
Tjulandin, Sergei
Ma, Wen Wee
Saleh, Mansoor N.
Harris, Marion
Reni, Michele
Ramanathan, Ramesh K.
Tabernero, Josep
Hidalgo, Manuel
Van Cutsem, Eric
Goldstein, David
Wei, Xinyu
Iglesias, Jose Luis
Renschler, Markus Frederic
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Evaluation of peripheral neuropathy in a phase Ill trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
Goldstein, D.
Von Hoff, D. D.
Moore, M.
Greeno, E.
Ritch, P.
Tortora, G.
Ramanathan, R. K.
Tabernero, J.
Ko, A.
Lu, B.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S613 - S613
[8] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
Goldstein, David
Von Hoff, Daniel D.
Chiorean, E. Gabriela
Reni, Michele
Tabernero, Josep
Ramanathan, Ramesh K.
Aly, Abdalla
Botteman, Marc
Wilkersen, Julia
Margunato-Debay, Sandra
Lu, Brian
Louis, Chrystal Ursula
Renschler, Markus Frederic
McGovern, Desmond Micahel Thomas
Lee, Chee Khoon
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
Kunzmann, Volker
Ramanathan, Ramesh K.
Goldstein, David
Penenberg, Darryl Neil
Ferrara, Stefano
Lu, Brian
Von Hoff, Daniel D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[10] Positron emission tomography (PET) response from a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients (pts) with metastatic adenocarcinoma of the pancreas
Ramanathan, R. K.
Von Hoff, D. D.
Moore, M.
Teixeira, L.
Siena, S.
Tabernero, J.
Goldstein, D.
Wei, X.
Lu, B.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611

← 1 2 3 4 5 →